Loading
Thrive Earlier Detection developed CancerSEEK, a blood test meant to find several kinds of cancer early in healthy adults during routine check-ups. Exact Sciences bought it, completing the deal in January 2021.
Thrive Earlier Detection worked on bringing earlier cancer detection into routine medical care, developing CancerSEEK, a liquid biopsy test designed to detect many cancers at earlier stages in healthy adults alongside existing screening (Third Rock Ventures). Exact Sciences announced on 27 October 2020 that it would acquire Thrive for cash and stock consideration of up to $2.15 billion, and completed the acquisition on 5 January 2021.
The Johns Hopkins blood test that first showed one draw could find several cancers and point to the organ; its approach passed to Thrive Earlier Detection and then to Exact Sciences, whose Cancerguard test followed.
Shares CancerSEEK, Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Exact Sciences (Abbott), Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/